- Home
- AVIR vs SLP Comparison
AVIR vs SLP Comparison
Compare AVIR & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVIR | SLP |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 399.3M | 370.7M |
| IPO Year | 2020 | 1996 |
Fundamental Metrics
Financial Performance| Metric | AVIR | SLP |
|---|---|---|
| Price | $5.00 | $18.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $10.00 | ★ $24.00 |
| AVG Volume (30 Days) | 351.2K | ★ 428.1K |
| Earning Date | 05-11-2026 | 04-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.00 | N/A |
| EPS | N/A | ★ 0.43 |
| Revenue | ★ $351,367,000.00 | $59,577,000.00 |
| Revenue This Year | N/A | $3.80 |
| Revenue Next Year | N/A | $5.90 |
| P/E Ratio | ★ N/A | $42.60 |
| Revenue Growth | N/A | ★ 10.52 |
| 52 Week Low | $2.78 | $11.09 |
| 52 Week High | $6.45 | $21.01 |
Technical Indicators
Market Signals| Indicator | AVIR | SLP |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.